Amundi Lowers Stake in Natera, Inc. (NASDAQ:NTRA)

Amundi reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 433,186 shares of the medical research company's stock after selling 40,930 shares during the quarter. Amundi owned approximately 0.33% of Natera worth $68,573,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in NTRA. Blue Trust Inc. lifted its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc lifted its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd lifted its stake in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares during the period. Principal Securities Inc. lifted its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the period. Finally, True Wealth Design LLC purchased a new stake in Natera in the third quarter worth about $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Morgan Stanley upped their price objective on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Piper Sandler boosted their target price on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. TD Cowen boosted their target price on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a report on Tuesday. Finally, Barclays initiated coverage on shares of Natera in a report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price for the company. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $173.56.

Remove Ads

Natera Price Performance

Shares of NASDAQ NTRA opened at $140.02 on Wednesday. The business's 50 day moving average price is $165.10 and its 200 day moving average price is $148.16. The firm has a market cap of $18.93 billion, a P/E ratio of -79.56 and a beta of 1.80. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. On average, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares of the company's stock, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John Fesko sold 669 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the sale, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 294,946 shares of company stock valued at $47,212,702 in the last three months. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.